The Schizophrenia drugs in development market research report provides comprehensive information on the therapeutics under development for Schizophrenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Schizophrenia. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Schizophrenia and features dormant and discontinued products.
GlobalData tracks 181 drugs in development for Schizophrenia by 126 companies/universities/institutes. The top development phase for Schizophrenia is preclinical with 60 drugs in that stage. The Schizophrenia pipeline has 171 drugs in development by companies and ten by universities/ institutes. Some of the companies in the Schizophrenia pipeline products market are: Luye Pharma Group, Cerevel Therapeutics and Terran Biosciences.
The key targets in the Schizophrenia pipeline products market include D2 Dopamine Receptor, 5-Hydroxytryptamine Receptor 2A, and 5-Hydroxytryptamine Receptor 1A.
The key mechanisms of action in the Schizophrenia pipeline product include Hydroxytryptamine Receptor 2A Antagonist with 33 drugs in Pre-Registration. The Schizophrenia pipeline products include ten routes of administration with the top ROA being Oral and six key molecule types in the Schizophrenia pipeline products market including Small Molecule, and Synthetic Peptide.
Schizophrenia overview
Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech, and disorganized behavior. Risk factors include family history, age, drugs (psychoactive), and weakened immune system. Treatment includes antipsychotic medications.
For a complete picture of Schizophrenia’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
